Abstract
S1082 Benefit-Risk Analysis of Point of Care Therapeutic Drug Monitoring vs Empiric Dose Escalation in Patients With Secondary Loss of Response to Infliximab
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
